Universitätsklinikum Ulm | Innere Medizin III
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants may or may not have already had treatment for their cancer. Participation could last up to six years.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Confirmed diagnosis of CLL/SLL requiring therapy per iwCLL 2018 criteria
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
Adequate organ function
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
650 participants in 2 patient groups
Loading...
Central trial contact
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal